SCHEMBL9907295

SCHEMBL9907295

NC(=O)CNC(Cc1ccc(N=O)cc1)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.43
EPHX1 P07099 1/20 0.34
MC5R P33032 2/20 0.34
MC1R Q01726 2/20 0.34
PTPN1 P18031 4/20 0.33
ALDH1A1 P00352 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GPR142 Q7Z601 1/20 0.33
ACE P12821 1/20 0.33
PTPN2 P17706 2/20 0.33
HPGDS O60760 2/20 0.33
PRSS1 P07477 1/20 0.33
TPSAB1 Q15661 1/20 0.33
PTPRA P18433 1/20 0.32
PTPN6 P29350 1/20 0.32
PTPN11 Q06124 1/20 0.32
PPARG P37231 1/20 0.32
ELANE P08246 1/20 0.32
MME P08473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4095860 0.77 CA2 (0.47) EPHX1ALDH1A1
SCHEMBL21417606 0.73 FPR2 (0.46) FPR2EPHX1ALDH1A1HSD17B10ACE
SCHEMBL9907283 0.72 KMT2A (0.42) FPR2ALDH1A1HSD17B10
SCHEMBL11719909 0.71 MME (0.51) ALDH1A1MME
SCHEMBL805214 0.70 FPR2 (0.56) FPR2ACEPPARGMME
SCHEMBL5597677 0.69 EPHX1 (0.51) EPHX1HPGDSELANEMME
SCHEMBL5597679 0.69 EPHX1 (0.51) EPHX1HPGDSELANEMME
SCHEMBL28218223 0.69 CA2 (0.59) ALDH1A1HSD17B10PRSS1TPSAB1
SCHEMBL17835186 0.69 FPR2 (0.61) FPR2PTPN1ALDH1A1ACEPPARG
SCHEMBL8374371 0.69 ACE (0.45) ACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120276001-A1 BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS Nordion (Canada) Inc (CA) 2012-11-01 US disclosed
US-8198101-B2 Bifunctional polyazamacrocyclic chelating agents NORDION (CANADA) INC. (CA) 2012-06-12 US disclosed
US-20090202521-A1 Bifunctional Polyazamacrocyclic Chelating Agents MDS (CANADA) INC. (CA) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090202521-A1 Bifunctional Polyazamacrocyclic Chelating Agents LPXN, FCGRT, POLQ FPR2 738/4885EPHX1 4043/4885MC5R 1192/4885
US-20120276001-A1 BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS LPXN, FCGRT, F13A1 FPR2 604/4885EPHX1 3965/4885MC5R 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.